MKRN2OS: A Drug Target / Disease Biomarker (G100129480)
MKRN2OS: A Drug Target / Disease Biomarker
MKRN2OS is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.
MKRN2OS is a short RNA molecule that consists of only 19 amino acid residues. It is located in the nucleus and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.
One of the key features of MKRN2OS is its ability to interact with other molecules in the cell. It has been shown to form a complex with the protein JNJ-352113, which is known to play a role in cell signaling and is often expressed in cancer cells. This interaction between MKRN2OS and JNJ-352113 has led to the speculation that MKRN2OS may be a drug target for cancer.
Another potential drug target for MKRN2OS is its role in cell apoptosis. MKRN2OS has been shown to be involved in the regulation of cell apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body. This function makes MKRN2OS an attractive target for drugs that are designed to promote apoptosis in cancer cells.
In addition to its potential as a drug target, MKRN2OS has also been identified as a potential biomarker for cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This makes MKRN2OS a promising candidate for use as a diagnostic marker for cancer.
The unique structure and function of MKRN2OS have also made it an attractive target for study. Its short size and simple sequence have made it easy to manipulate and study using various techniques, such as RNA interference and mass spectrometry. These studies have provided valuable insights into the biology of MKRN2OS and its potential as a drug target and biomarker.
In conclusion, MKRN2OS is a non-coding RNA molecule that has shown promise as a drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for research and development of new treatments. Further studies are needed to fully understand the biology of MKRN2OS and its potential as a drug and biomarker.
Protein Name: MKRN2 Opposite Strand
The "MKRN2OS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKRN2OS comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3
